Sultanate of Oman Ministry of Health Drug Safety Center Muscat



سلطنة عُمان وزارة الصحة مركز سلامة الدواء مسقط

To:

THE DIRECTOR GENERAL OF HEALTH SERVICES IN ALL GOVERNORATES

Commanding Officer, Armed Forces Hospital (Al Khoudh & Salalah)

Director General of Engineering Affairs, MOH

Director General of Royal Hospital

Director General of Khoula Hospital

Director General of Medical Supplies (MOH)

Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Hospitals)

Hospital Director (Al Nahda Hospital)

Hospital Director (Al Massara Hospital)

The Head of Medical Services in SQU Hospital

The Head of Medical Services in Royal Oman Police

The Head of Medical Services in Ministry of Defence

The Head of Medical Services in The Diwan

The Head of Medical Services in The Sultan's Special Force

The Head of Medical Services in Internal Security Services

The Head of Medical Services in Petroleum Development of Oman

The Head of Medical Services in LNG Oman

ALL PRIVATE PHARMACIES & DRUG STORES

After Compliments,

Please find attached our Circular No 165 dated 28 / 11 / 24 Regarding SFDA Field Safety Notice of Access hsTnI (reagent pack) from (mfr: Beckman Coulter Inc).

Copy to:

- · Director, Office of H.E. The Undersecretary for Health Affairs
- Director of Medical Device Control, DSC
- Director of Pharmacovigilance & Drug Information Dept, DSC
- Director of Drug Control Department, DSC
- Director of Pharmaceutical Licensing Department, DSC
- Director of Central Quality Control Lab., DSC
- Supdt. of Central Drug Information





Sultanate of Oman **Ministry of Health Drug Safety Center** Muscat



وزارة الصحــة مركز سلامة السدواء

Circular No. | 65/2024

26-05-1446 H 28 -11-2024

Field Safety Notice of Access hsTnI (reagent pack) from Beckman Coulter Inc.

Source	SFDA- Saudi Food & Drug Authority. https://ade.sfda.gov.sa/Fsca/PublishDetails/189		
Product	Access hsTnI (reagent pack).		
Manufacturer	Beckman Coulter Inc.		
Local agent	Muscat Pharmacy & Stores LLC.		
The affected products	B52699.		
Reason	In remote circumstances according Beckman Coulter, if a sample containing high cardiac troponin (cTnI) >55,000 pg/mL is tested using an Access assay other than Access hsTnI, cTnI carryover may occur if the next test performed, using the same probe on that instrument, is Access hsTnI on a different sample.		
Action	 Follow your established laboratory protocols for analyzing and retesting discrepant samples if an observed Access hsTnI test result does not align with the patient's clinical presentation. Beckman Coulter recommends reviewing the content of the attachment with you laboratory and/or medical director to determine appropriate next steps. Contact the local agent for remedial action. 		
comments	Healthcare professionals are encouraged to report any adverse events Suspected to be associated with the above device or any other medical device to Department of Medical Device Control through the E-mail: vigilance-md@moh.gov.om		

Dr. Mohammed Hamdan Al Rubaie Director General











November 07, 2024

URGENT MEDICAL DEVICE RECALL

Access hsTnI Reagent Kit*

REF	LOT	
B52699	All	NA

*When run on the Access 2, UniCel Dxl 600, UniCel Dxl 800, UniCel DxC 600i, UniCel DxC 660i,

UniCel DxC 680i, UniCel DxC 860i, UniCel DxC 880i and DxC 500i systems.

This Medical Device Recall does not affect the DxI 9000 Access Immunoassay

Analyzer.

Attention Beckman Coulter Customer,

Beckman Coulter is initiating a field action for the product listed above. This letter contains important information that needs your immediate attention.

ISSUE:	 In remote circumstances, if a sample containing high cardiac troponin (cTnI) >55,000 pg/mL is tested using an Access assay other than Access hsTnI, cTnI carryover may occur if the next test performed, using the same probe on that instrument, is Access hsTnI on a different sample. 	
IMPACT:	 Carryover of cTnl may generate a falsely elevated Access hsTnl result in subsequent sample(s) which can impact patient care (potentially but not limited to unnecessary coronary imaging or diagnostic catheterization) if the result is near the medical decision points. One internal study indicated the potential for carryover of 2-5 pg/mL from a high cTnl sample (~55,000 pg/mL). 	
ACTION:	 Follow your established laboratory protocols for analyzing and retesting discrepant samples if an observed Access hsTnl test result does not align with the patient's clinical presentation. Beckman Coulter recommends reviewing the content of this letter 	
	with your laboratory and/or medical director to determine appropriate next steps.	
RESOLUTION:	Beckman Coulter is currently investigating options to resolve this issue.	



Please share this information with your laboratory staff and retain this notification as part of your laboratory Quality System documentation. If you have forwarded the affected product listed above to another laboratory, please provide them a copy of this letter.

So that we are assured you have received this important communication, please respond within 10 days in one of the following ways:

- Electronically, if you received this communication via email.
- Manually, complete and return the enclosed Response Form.

If you have any questions regarding this notice, please contact our Customer Support Center:

• From our website: http://www.beckmancoulter.com

We apologize for the inconvenience that this caused your laboratory.

Sincerely,

—Signed by:

Courtney Walton

n

Signer Name: Courtney Walton

Signing Reason: I approve this document Signing Time: 07-Nov-2024 | 2:10:40 PM PST

-A78060F7687943039615B491616B80F6

Courtney Walton

Senior Director of Quality Assurance and Regulatory Affairs

Beckman Coulter, Inc.

Enclosure: Response Form

© 2024 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo and the Beckman Coulter product and service names mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.